Embryonic stem cells go from bench to bedside for Parkinson’s disease
Clare L. Parish, Lachlan H. Thompson
Cell Reports Medicine · 2021
doi:10.1016/j.xcrm.2021.100251 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Stem-cell-derived transplants may soon be a promising treatment option for Parkinson’s disease. In preparation for clinical trial, Piao et al.1 report on generating a clinical-grade dopaminergic progenitor cell product and its rigorous testing to ensure safety and efficacy.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.